

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/506,827	09/07/2004	Janusz B. Pawliszyn	PAT 804W-2 8910		
26123	7590 06/30/2005	EXAMINER			
BORDEN LADNER GERVAIS LLP WORLD EXCHANGE PLAZA			DIRAMIO, JACQUELINE A		
	STREET SUITE 1100	ART UNIT	PAPER NUMBER		
OTTAWA, ON KIP 1J9			1641		
CANADA			DATE MAILED: 06/30/2009	DATE MAILED: 06/30/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.	Applicant(s)				
Office Action Summary		10/506,827	•	PAWLISZYN, JANUSZ B.				
		Examiner		Art Unit				
		Jacqueline D	iRamio	1641				
	- The MAILING DATE of this communicat			orrespondence ad	ldress			
Period for Reply .								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status			(
1) 🛛	Responsive to communication(s) filed o	n <i>05 March 2005</i> .						
·	☐ This action is FINAL . 2b) ☐ This action is non-final.							
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4) ☐ Claim(s) 101-110 is/are pending in the application. 4a) Of the above claim(s) 96-100 and 111-116 is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 101-110 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement.								
Application	on Papers							
 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on <u>07 September 2004</u> is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 								
Priority under 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
	e of References Cited (PTO-892)	4)	Interview Summary					
3) 🔯 Inform	e of Draftsperson's Patent Drawing Review (PTO- nation Disclosure Statement(s) (PTO-1449 or PTO No(s)/Mail Date <u>12/7/2004</u> .	D/SB/08) 5)	Paper No(s)/Mail Da Notice of Informal Pa Other:		D-152)			

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 96 – 100, drawn to a method for measuring or identifying a component.

Group II, claim(s) 101 – 110, drawn to a device for collecting a component from an animal or animal tissue.

Group III, claim(s) 111, drawn to a method for measuring or identifying a component in an animal or animal tissue.

Group IV, claim(s) 112 and 113, drawn to a method of measuring or identifying a component in a plurality of liquid samples.

Application/Control Number: 10/506,827

Art Unit: 1641

Group V, claim(s) 114, drawn to a device for measuring or identifying a component in a plurality of liquid samples.

Group VI, claim(s) 115, drawn to a microextraction method for measuring a component in a sample.

Group VII, claim(s) 116, drawn to a method for calibration of an analytical instrument.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Groups I – III appears to be the device of Group II for measuring or identifying a component.

However, the common technical feature of the device of Group II is known in the art as shown by Pawliszyn [US 5,691,206] for a device for solid phase microextraction and desorption. Therefore, the technical feature linking Groups I – III does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Groups IV and V relate to a separate device not required by any of the other groups and Groups VI and VII relate to different methods and method steps not required

Art Unit: 1641.

by any of the other groups. Therefore, the inventions do not form a general inventive concept, as they do not share a common special technical feature.

During a telephone conversation with Kathleen Marsman on June 17, 2005 a provisional election was made without traverse to prosecute the invention of Group II, claims 101-110. Affirmation of this election must be made by applicant in replying to this Office action. Claims 96-100 and 111-116 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Specification

The disclosure is objected to because of the following informalities:

- 1) Variable **7** of Figure 1 part A is referred to on page 16, line 21, but this variable is not disclosed on figure 1 part A.
 - 2) Line 1, page 20, word "and" is misspelled as "ad" between 66 and 64.
 - 3) Page 23, line 13, term "this is demonstrated this" is an unclear phrase.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 110 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 110 recites the limitation "in a form suitable," which is vague and indefinite because it is unclear what defines a suitable form.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 101, 107, 109 and 110 are rejected under 35 U.S.C. 102(b) as being anticipated by Pawliszyn (US 5,691,206).

Pawliszyn teaches a device for solid phase microextraction comprising a fiber, which contains a coating selective for a component of interest (extraction phase), and a hollow needle (positioning device), which contains the fiber and allows for positioning into a sample for microextraction (see column 2, lines 10-21 and Figure 3 in particular). For solid phase microextraction, the extraction process "does not require prior sampling"

Application/Control Number: 10/506,827

Art Unit: 1641

of aqueous material since in-vivo or in-vitro sampling can be conveniently performed," therefore, the device is enabled for positioning of the fiber in animal or animal tissue (see column 5, lines 10-15 in particular).

With respect to claim 107, the hollow needle is further connected to a syringe, which acts as a housing (openable) for the fiber (see column 3, lines 52-56).

With respect to claim 109, the device allows for fiber or fibers to be utilized for the microextraction process (see column 3, lines 53-65 in particular).

With respect to claim 110, the device containing the syringe and fiber is utilized with an analytical instrument (e.g. a gas chromatograph) (see column 4, lines 46-58 in particular).

Claims 101, 107 and 110 are rejected under 35 U.S.C. 102(b) as being anticipated by Frerot et al. (Solid-Phase Microextraction (SPEM): A new tool in pheromone identification in lipidoptera, *J. High Resol. Chromatogr.* 1997, 20, pp.340-342).

Frerot et al. teach a device for solid-phase microextraction (SPME) utilizing a SupelcoTM SPEM holder (positioning device) equipped with a fiber coated with polydimethylsiloxane (extraction phase), wherein the fiber extracts pheromone components from the glands (tissue) of Lepidoptera (animal/insect) (see p340, materials and methods).

With respect to claim 107, the SupelcoTM SPEM holder utilized by Fretot et al. comprises a similar embodiment to the device of Pawliszyn as described above, with a hollow needle (positioning device), which contains the fiber, and a syringe forming the entire housing for the device (see sigmaaldrich.com).

With respect to claim 110, the fiber with the extracted components was analyzed using a gas chromatograph by insertion of the fiber into the analytical instrument (see p341, second paragraph).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claim 108 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pawliszyn (US 5,691,206) or Fretot et al. ((Solid-Phase Microextraction (SPEM): A new

tool in pheromone identification in lipidoptera, *J. High Resol. Chromatogr.* 1997, 20, pp.340-342) in view of Van Bockel (US 6,743,180).

Both Pawliszyn and Fretot et al., which have been discussed above in the 102 rejection, fail to teach the use of a catheter with the positioning device.

Van Bockel teaches the use of a catheter for introducing a device, i.e. pressure sensor, into an artery. The catheter has an advantage for introducing the device into the body because only a very small operation is required and the catheter allows for the device to be effectively introduced and directed to the proper position (see column 2, lines 20-30 in particular).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to include with the device taught by both Pawliszyn and Fretot et al. a catheter as taught by Van Bockel because Van Bockel teaches the benefit of using a catheter to introduce a device into an artery because only a very small operation is required and the catheter allows for the device to be effectively introduced and directed to the proper position.

Claims 102 and 103 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pawliszyn (US 5,691,206) or Fretot et al. ((Solid-Phase Microextraction (SPEM): A new tool in pheromone identification in lipidoptera, *J. High Resol. Chromatogr.* 1997, 20, pp.340-342) in view of Basta (US 6,730,096).

Pawliszyn and Fretot et al. further fail to teach the use of a biocompatible protection layer coated on the fibre, wherein the biocompatible layer comprises polypyrrole or derivatised cellulose.

A biocompatible component is one that has compatibility with living tissue or a living system by not being toxic, injurious, or physiologically reactive and not causing immunological rejection (Merriam-Webster's Collegiate Dictionary). Many references teach the use of cellulose derivatives for biocompatible coatings on surgical or implantable devices. Basta teaches a catheter and stabilizing device wherein both the catheter and device are formed of a biocompatible plastic or elastomer, such as a cellulose derivate, i.e. cellulose acetate, which will therefore not cause a toxic or injurious response within the body (see column 5, lines 35-60 in particular).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to include on the fiber taught by both Pawliszyn and Fretot et al. a coating comprising a biocompatible protection layer, such as a cellulose derivative, as taught by Basta because it is beneficial to use a biocompatible coating on any device used within the body in order to prevent a toxic or injurious response.

Claim 106 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pawliszyn (US 5,691,206) or Fretot et al. ((Solid-Phase Microextraction (SPEM): A new tool in pheromone identification in lipidoptera, *J. High Resol. Chromatogr.* 1997, 20, pp.340-342) in view of Quay et al. (US 6,287,521).

The devices taught by both Pawliszyn and Fretot et al. contain fibers coated with an extraction phase comprised of polydimethylsiloxane, but fail to teach the use of a fluorescent label or enzyme contained within the extraction phase.

Quay et al. teach the use of a solid phase matrix, such as capillary or coated tubes (hollow fibers), to extract biological markers from mammary fluid (see column 12, lines 8-17 in particular). Reagents, such as immobilized antibodies (bioaffinity agent), are attached to the solid phase matrix in order to bind to the target compound in the sample (see column 12, lines 20-40 in particular). Quay et al. further teach the combination of the solid phase matrix comprising the immobilized antibodies (bioaffinity agent) with a label, such as an enzyme or fluorescent label, which function to display the presence or absence of the target analyte by reacting with the target (see column 12, lines 51-67 in particular).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to include on the fiber taught by both Pawliszyn and Fretot et al. an extraction phase comprising immobilized antibodies (bioaffinity agent) and a fluorescent label or enzyme as taught by Quay et al. because Quay et al. teach the benefit of using the immobilized antibodies to bind the target of interest and the benefit of a fluorescent label to display the presence or absence of this target analyte.

Claim 104 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pawliszyn (US 5,691,206) or Fretot et al. ((Solid-Phase Microextraction (SPEM): A new tool in pheromone identification in lipidoptera, *J. High Resol. Chromatogr.* 1997, 20, pp.340-342) in view of Colburn et al. (US 2003/0183758).

Both Pawliszyn and Fretot et al. meet the structural limitations of both the fiber and extraction phase, therefore, enabling the device to be useful in a variety of analytical instruments, however, Pawliszyn and Fretot et al. fail to teach the use of MALDI-TOFMS analysis specifically.

Colburn et al. teach that matrix-assisted laser desorption/ionization (MALDI) in combination with time-of-flight (TOF) analyzers have become one of the standard approaches to characterization by mass spectrometry of non-volatile, thermally labile substances such as peptides, proteins and polymers (see paragraph 0003, in particular).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to include the MALDI-TOFMS combination as taught by Colburn et al. as the analytical instrument for the device of Pawliszyn and Fretot et al. because Colburn et al. teach the benefit of using MALDI-TOF analyzers because they have become one of the standard approaches to characterization by mass spectrometry of non-volatile, thermally labile substances such as peptides, proteins and polymers.

Claim 105 is rejected under 35 U.S.C. 103(a) as being unpatentable over Pawliszyn (US 5,691,206) or Fretot et al. ((Solid-Phase Microextraction (SPEM): A new

tool in pheromone identification in lipidoptera, *J. High Resol. Chromatogr.* 1997, 20, pp.340-342) in view of Riviere et al. (US 2003/0180954).

Pawliszyn and Fretot et al. further fail to teach the addition of a calibrant to the extraction phase of the fiber.

Riviere et al. teach the use of polydimethylsiloxane coated fibers as skin-imitating membranes in order to study permeation of chemicals into these membranes (see paragraph 0037). The absorption parameters, referred to as molecular descriptors, of each chemical compound is obtained by comparing to its calibration standard, wherein the standards were created by analyzing fifty compounds and their subsequent molecular descriptors (see paragraphs 0167-0169). The calibration standards determine the system constants, which reflect the properties of the membrane (fibers) and will not change with different solutes, therefore, the molecular descriptors of unknown/study compounds can be obtained (see paragraph 0170).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to include on the extraction phase of the fibers of Pawliszyn and Fretot et al. a calibration standard (calibrant) as taught by Riviere et al. because Riviere et al. teach the benefit of using calibration standards to determine the system constants because they reflect the properties of the fibers, which will not change and thus enable the absorbance of unknown compounds to be studied.

Conclusion

No claims are allowed.

Application/Control Number: 10/506,827

Art Unit: 1641

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacqueline DiRamio whose telephone number is 571-272-8785. The examiner can normally be reached on M-F 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jackie DiRamio Patent Examiner Art Unit 1641

LONG V. LE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

06/27/05

Page 13